IDEXX Laboratories' Net Income Soars 45% in Strong Q2 Performance

Core Financial Results

IDEXX Laboratories, Inc. reported second quarter 2025 revenue of $1,109 million, an 11% increase compared to $1,003 million in Q2 2024. This growth was primarily driven by the Companion Animal Group (CAG) and Water segments. Net income for the quarter also saw a significant rise, reaching $293 million, a 45% increase from $203 million in the prior year period. Diluted EPS stood at $3.63, exceeding the analyst estimate of $3.28, indicating a beat on earnings expectations.

Key Performance Drivers

The company's strong performance was largely attributable to the Companion Animal Group, which recorded 11% reported and 10% organic growth. CAG Diagnostics recurring revenue grew 9% as reported and 7% organically, with particularly strong gains in International regions (15% reported, 11% organic). Key drivers within CAG included IDEXX VetLab® consumables, which saw 15% reported and 14% organic revenue growth, and record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ placements. Reference laboratory diagnostic and consulting services also contributed with 6% reported and 5% organic revenue growth, driven by higher testing volumes and net price gains.

Water revenues grew 9% as reported and 8% organically, reflecting solid growth across major regions and double-digit International growth. Livestock, Poultry, and Dairy (LPD) revenues increased 5% as reported and 3% organically, led by commercial execution in North America and Asia Pacific. Gross profit increased 12% as reported, with gross margin expanding by 90 basis points to 62.6%, supported by strong growth in VetLab consumables and productivity initiatives in Reference Labs.

Management Outlook

IDEXX management expressed confidence in their innovation-driven strategy, highlighting the exceptional momentum with IDEXX InVue Dx™ placements. The company has increased its full-year 2025 revenue guidance to a range of $4,205 million to $4,280 million, representing a 7.7% - 9.7% reported growth. This upward revision reflects solid CAG Diagnostics recurring revenue performance, anticipated higher IDEXX inVue Dx™ instrument placements, and a $70 million benefit from foreign exchange impacts.

The company also updated its 2025 EPS outlook to $12.40 - $12.76, marking a $0.40 increase from prior guidance midpoint. This revised outlook is supported by increased revenue and operating profit margin expectations, a lower effective tax rate, and favorable foreign exchange adjustments. The updated EPS growth outlook is 16% - 20% as reported and 9% - 13% on a comparable basis.